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RNA IN BIOLOGY AND MEDICINE 
 
Ribonucleic acids (RNA) participate in many cellular 
processes including protein translation, signalling, 
and regulation [1, 2]. The first function of RNA 
identified was the transfer of information from 
deoxyribonucleic acid (DNA) to proteins. The RNA 
was termed messenger RNA or mRNA [3]. In this 
model DNA is responsible for information storage 
and proteins are responsible for catalytic function [4, 
5], with RNA simply serving as a carbon copy of 
DNA. The discovery that RNA was capable of 
catalyzing RNA cleavage changed the perception of 
RNA’s function [6, 7]. RNA sequences that are 
capable of catalytic activity are called ribozymes. 
This discovery led to the proposal of the RNA world 
hypothesis which suggests that early life went 
through a stage where RNA was responsible for 
information storage and catalytic function [8]. 
 
RNA in translation 
 
The discovery of mRNA was followed by the 
identification of ribosomal RNA (rRNA) [9] and 
transfer RNA (tRNA) [10]. rRNA interacts with 
specific proteins to form the ribosome [11] which is 
responsible for translation of mRNA code to protein 
sequence. It achieves this through interactions with 
tRNA and mRNA [12]. tRNA assists the 
transcription of codons by acting as a translator [13]. 
The ribosome brings together mRNA, based on 
complementary interaction of mRNA codon and 
tRNA anti-codon [14]. This is followed by the 
peptidyl transferase reaction which is catalyzed by 
the ribosome. [15]. The discovery that the RNA 
component of the ribosome is responsible for the 
catalytic activity further emphasizes the central role 
that RNA plays in biochemistry and supports the idea 
of an RNA world at the origin of life. This function 
of RNA showed that large proteins required RNA to 
be synthesized and were possible after RNA 
developed this ability [16]. 
 
RNA in regulation 
 
In the past 20 years more classes of RNA with 
diverse functions have been identified; these include 
small interfering RNA  (siRNA) [17], micro RNA 
(miRNA) [1], small nucleolar RNA (snoRNA) [18], 
piwi interacting RNA (piRNA) [19], long non-coding 
RNA (lncRNA) [20] and riboswitches [21]. In 
addition to these, RNA has also been observed 
recently to function as an extracellular signalling 
molecule [22]. These RNAs functions in conjunction 
with protein molecules to achieve gene regulation.  
siRNA and miRNA are short sequences of RNA that 
form double stranded strands with target RNAs via 
Watson Crick base pairing. These double stranded 
RNAs are then targeted by cellular degradation 
mechanisms [23]. The difference between siRNA and 
miRNA lies in the role they play in cellular 
biochemistry. siRNA are largely regarded as defense 
against exogenous RNA while miRNA is responsible 
for regulation of endogenous genes [24]. snoRNAs 
identify RNA for modification and guide proteins to 
the modification sites. These modifications, including 
methylation and pseudouridylation, are important for 
proper folding in rRNA and tRNA [25]. piRNA are a 
testis specific class of RNA. They participate in gene 
silencing similar to miRNA and siRNA, and have 
been found to target sequences that are prone to 
relocating themselves within the genome also known 
as transposons [26]. With the exception of mRNA the 
above mentioned RNA are non-coding RNA 
(ncRNA), meaning that they have function other than 
providing the code for translation.  Long ncRNA are 
ncRNA that are longer than 200 nucleotides. lncRNA 
can be processed to make siRNA or miRNA but are 
also functional as regulators in long form [20]. 
Riboswitches are sequences of RNA that bind to a 
specific small molecule target. The binding event 
causes a change in structure that regulates 




The diverse and central roles that RNA plays in cells 
make it an appealing target for molecular therapeutic 
and diagnostic applications. RNA can be a candidate 
for a potential drug molecule itself due to the variety 
of molecules it can interact with. Using systematic 
evolution of ligands by exponential enrichment 
(SELEX) [28, 29] it is possible to select for an RNA 
sequence that targets a specific molecule or cell type. 
RNA sequences with a high affinity for a specific 
target are referred to as aptamers [28]. Even though 
this term was initially only applied to RNAs that 
were selected in vitro, it has since been expanded to 
include naturally occurring aptamers. These natural 
aptamers include riboswitches which are not only 
able to bind to a specific target but also play a role in 
gene regulation [27].   
Currently there are several aptamers in phase I and II 
clinical trials [30]. These include aptamers for 
treatment of coronary artery bypass [31], macular 
degeneration [32] and acute myeologenous leukemia 
[33]. Macugen is an aptamer based drug that targets 
vascular endothelial growth factor (VEGF) currently 
available for treatment of macular degeneration [34]. 
This aptamer is conjugated to a polyethylene glycol 
(PEG) to increase its lifetime in vivo. PEG increases 
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the lifetime of biomolecules in vivo by changing the 
biomolecules hydrophobicity and electrostatic 
binding properties [35]. PEGylation turns the main 
disadvantages of RNA drugs, the low lifetime due to 
degradation, into an advantage by allowing tailoring 
of the lifetime of the drug based on size of PEG. It 
should be mentioned that therapeutics developed with 
siRNA [36] and ribozymes [37] have also shown 
some promise and several clinical trials are in 
progress. However, a detailed discussion of these 
systems is beyond the scope of this review. 
 
Research into the nature of the interactions between 
target and drug molecule has helped to improve 
protein targeting molecules. For example, in the case 
of protein kinase inhibitors structural work revealed 
non catalytic sites that could be targeted [38]. 
Investigation into the structure of VEGF and aptamer 
binding has revealed the interaction with the VEGF 
heparin binding domain [39]. More recently, the 
same approach is being taken with RNA targeting 
small molecules by using aptamer models to 
understand nature of interactions between RNA and 
small molecules.  
 
This review attempts to provide an overview of the 
structural and thermodynamic information currently 
available for RNA aptamer interactions with proteins, 
RNA and small molecules. These studies form a 
crucial foundation for applying medicinal chemistry 
approaches to novel targets involving RNA.  
 
LARGE BIOMOLECULE RNA APTAMER 
INTERACTIONS   
 
Much effort has been directed at developing aptamers 
that target the human immunodeficiency virus (HIV) 
by specifically targeting the HIV regulator of virion 
expression (Rev) peptide, trans-activation response 
element (TAR) HIV RNAs or the HIV trans activator 
of transcription (Tat) peptide [40 – 42].  
 
HIV Rev peptide  
 
The HIV Rev peptide binds to the envelope gene at 
the Rev response element site. It is responsible for 
transporting mRNA that encodes viral proteins to the 
cytoplasm [43 – 44]. The studies of the structures of 
HIV rev peptide in complex with RNA aptamers 
demonstrate how RNA can influence the structure of 
its ligand. Depending on the RNA sequence the 
peptide binds in either a α-helical or elongated 
conformation [42, 46]. This knowledge is important 





The HIV Tat peptide binds to the TAR HIV RNA 
and is necessary for transcription initiation, a vital 
part of the viral life cycle [47]. The HIV Tat aptamer 
complex was initially studied by using the simplest 
analog of Tat, an argininamide molecule [41]. 
Argininamide was used as an analog of Tat since the 
peptide is arginine rich and an arginine residue was 
implicated in binding to the TAR region [48]. This 
structure revealed the aptamer was binding two 
argininamide molecules suggesting that it interacts 
with two arginine residues on the peptide [41]. 
Inhibition of binding of Tat to TAR was observed 
when Tat is captured by aptamer, demonstrating that 
the aptamer is binding either at or near the TAR 
binding site [49]. 
 
 
TAR-HIV RNA  
 
The interaction of the aptamer selected against TAR-
HIV RNA reveals a kissing complex where non 
canonical RNA-RNA interactions along with 
stacking interactions create a stable intermolecular 
structure (Figure 1) [50].  These types of complexes 
are important to the viral life cycle. For example, the 
HIV-1 genomic RNA dimerization initiation site 
(DIS) kissing complex formed by two DIS elements 
triggers viral RNA dimerization [51]. It has been 
shown that the hydrogen bonding network within the 
kissing complex along with intermolecular stacking 
interactions is responsible for molecular recognition 








Figure 1.   HIV related RNA aptamers. Aptamers in black, Target molecules in grey. A) TAR – TAR 
aptamer complex, PDB ID 2RN1 [50], showing the “kissing” interaction. B) HIV Tat aptamer in 
complex with two argininamide molecules, PDB ID 1NBK [41], showing the RNA wrapped 
around the molecules. C) HIV Rev peptide aptamer complex, PDB ID 1ULL [46], showing the 
peptide in the groove of the RNA. D) HIV Rev peptide aptamer complex, PDB 484D [42], 
showing the extended peptide bound to aptamer. Figure was generated using UCSF Chimera [52]. 
 
 
MS2 coat protein 
 
Another virus that has been targeted for aptamer 
development is bacteriophage MS2. This virus has 
been used as a model system to study RNA-protein 
interactions [53, 43]. The MS2 coat protein is 
responsible for recognition of a stem loop within the 
genome and binding to this loop is part of a process 
that initiates encapsidation [55].  Structural 
investigations of this aptamer and MS2 coat protein 
revealed that the aptamer binds to the protein in a 
similar manner to other stem loop RNA’s. This 
binding interaction involves the phosphodiester 
backbone of the RNA. Phosphates of the backbone 
undergo subtle rearrangements that lead to different 
affinities when mutations were studied. The effect of 
rearrangement of the phosphate backbone changes 
the hydrogen bonding network, Horn et al. suggest 
that predicting these changes will lead to better de 




Viral RNA interactions are not the only RNA 
interactions of interest that have been addressed by 
aptamer development. Other targets include RNA 
polymerases and initiation factors. RNA polymerases, 
the enzymes responsible for transcription of DNA to 
RNA can be inhibited by binding of RNA molecules 
[57, 58].  Structural work on the RNA aptamer bound 
to RNA polymerase II (Figure 2A) highlighted a 
possible mechanism for inhibition. The aptamer 
binding blocks the initiation center so template DNA 
cannot reach the catalytic center. B2 RNA is a 
ncRNA that supresses mRNA transcription by 
inhibiting RNA polymerase II in response to heat 
shock [59]. Competitive binding of B2 RNA and 
RNA polymerase II RNA aptamer to RNA 
polymerase II was investigated by Kettenberger et al. 
The absence of B2 RNA binding revealed by these 
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experiments suggests that B2 RNA may bind in the 
same way as the aptamers [60].  The 6S RNA also 
binds to RNA polymerase II. Based on the RNA 
aptamer that binds in A-form within the RNA 
polymerase II cleft it was suggested that this maybe 
how 6S RNA binds [58]. This observation expands 
the understanding of how the RNA polymerase II 
cleft interacts with RNA, in addition to 
accommodating B-form DNA templates [60].
 
Figure 2. RNA aptamer (black) bound to protein targets (grey) A) MS2 coat protein, PDB ID 1U1Y [56], 
showing the loop interaction between protein and RNA. B) RNA polymerase II, PDB ID 2B63 
[60], showing the aptamers buried within the polymerase. C) NF-κb homodimer, PDB ID 1OOA 
[61], showing the RNA helix interacting with protein. D) Human IgG, PDB ID 3AGV [70], 
showing interaction between RNA and specific site on protein (Tyr 333). E) Prion protein aptamer, 
PDB ID 2RQJ [66], this structure lacks the target protein, however the quadruple structure shown 
here is key to the interaction with protein, in this case both black and grey represent RNA.  Figure 
was generated using UCSF Chimera [52]. 
 
Transcription and Initiation factors  
 
Transcription factors are proteins that bind to the 
DNA sequences regulating transcription. The NF-b 
factor is involved in activating genes and has been 
the target of therapeutic inhibition of cancer cells 
[62]. In the case of the mammalian transcription 
factor NF-b binding, the RNA aptamer mimics 
DNA structure (Figure 2B). The pre-bound structure 
of the RNA resembles B-form DNA. The RNA upon 
binding to NF-b adapts to the presence of the 
protein [63]. Initiation factors are proteins that bind 
to the ribosome during translation. The mammalian 
initiation factor 4A binding interaction with its RNA 
aptamer were studied by obtaining structures of 
individual RNA aptamer loops and evaluating the 
interactions with the initiation factor.  These studies 
suggest that binding involves the interaction of the 
aptamer’s AUCGCA loop with the initiation factor 
[64].  Future structural work may reveal how these 
aptamers could interfere with the different factors and 




RNA aptamers have also been used to study protein 
targets whose primary function does not involve 
interaction with RNA, such as prion proteins and 
immunoglobulins. Prion proteins are infectious 
particles responsible for diseases like Creutzfeldt 
Jacob disease and spongiform encephalopathy [65]. 
The RNA aptamer for bovine prion utilizes the 
electrostatic interaction between its phosphate 
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backbone and lysine clusters, along with stacking 
interactions between its GGGG quadruplex and a 
tryptophan residue to achieve binding [66]. Prion 
protein has been found to bind to amyloid–β 
oligomers leading to synaptic dysfunction. This 
aptamer has been proposed for development as a 
therapeutic agent for Alzheimer's disease, since the 
prion protein plays a role in impairment of synaptic 
plasticity [67]. The prion aptamer has already been 
shown to reduce the formation of prion protein in 
infected cells, most likely by preventing prion protein 
from interacting with native proteins [68]. 
 
Human immunoglobulin G 
 
Human immunoglobulin G (IgG) is a protein 
responsible for identifying pathogens [69]. The 
structure of human IgG bound to its aptamer reveals 
the interactions that make the RNA specific for this 
particular immunoglobulin. The interactions involve 
stacking of bases with Tyr373; unlike other protein 
RNA interactions the binding is not driven by the 
interaction of negatively charged phosphate and 
positively charged surface of protein [70]. This is 
significant because it has expanded the type of ligand 









he antibiotics that target rRNA have been 
investigated further by the development of aptamers 
that bind them with high affinity and specificity. 
Neomycin B is an aminoglycoside antibiotic that 
inhibits a variety of RNA-mediated biological 
functions [71]. The structure-function relationship of 
Neomycin B and other aminoglycosides has been 
studied in detail with respect to the ribosome. Two 
binding sites have been identified, one on helix 44 of 
the small ribosomal unit and the other on helix 69 of 
the large ribosomal subunit.  In the small ribosomal 
subunit, neomycin binds within a pocket formed by 
an A:A base pair and an unpaired A. These residues 
are responsible for increasing affinity to cognate 
tRNA–mRNA pairings. With the antibiotic bound the 
ribosome is immobilized into a high affinity 
configuration that recognizes both cognate and non-
cognate tRNA-mRNA complexes thereby leading to 
miscoding [72].  In the large ribosomal subunit it 
binds within helix 69 with binding stabilized by 
contacts including a CAAUAC loop and G1906. This 
helix is swung away from an interface of subunit 
association by the ribosome recycling factor (RRF). 
Binding of the antibiotic restores interactions 
destabilized by the RRF and inhibits ribosome 
recycling [73].  The structure of Neomycin B in 
complex with HIV-1 DIS (previous mentioned) has 
since been crystallized. This binding interaction is 
similar to that involved in the small ribosomal unit 
[74 – 76]. These structures reveal that the mode of 
interaction between RNA and Neomycin B can vary.  
The binding of Neomycin B to its aptamer has been 
investigated to obtain a better understanding of 
aminoglycoside-RNA interactions, Figure 3 shows a 
few of the different structures of Neomycin B RNA 
binding pockets.  
  
Neomycin B binds to the aptamer within a pocket 
consisting of three consecutive GU base pairs and a 
flap formed by an adenine base [77]. This pocket is 
different from the aforementioned binding sites. 
Further investigation of this interaction showed that 
hydrogen bonding interactions between aptamer and 
ligand are the major mechanism responsible for 
binding [79].  A more recent study used NMR 
techniques to show that protonation of Neomycin B 
accompanies binding its cognate aptamer, 
demonstrating the ability of RNA to influence its 
ligand [80]. The thermodynamic differences in 
binding of these complexes and other RNA 
complexes will be discussed in the following section. 
Other antimicrobial agents have been used as targets 
for development of aptamers. These include 
tetracycline, tobramycin and streptomycin. 
Characterization of these complexes has illuminated 
different aspects of RNA small molecule interactions 
and most of these aptamers have also been used to 
develop biosensors for medical applications [80]. For 
example the tobramycin aptamer has been 
incorporated as part of an aptasensor that can detect  
tobramycin and other aminoglycosides in human 





Figure 3.  Neomycin B bound to RNA. A) Neomycin B aptamer, PDB ID 1NEM [77], B) HIV TAR, PDB                    
ID 1QD3 [78], C) 30S ribosome Neomycin binding site, PDB ID 2QAN [73], D) 50S ribosome 
Neomycin B binding site, PDB ID 2QAO [74], E) HIV DIS complex, PDB ID 3C7R [75]. 
Neomycin B is coloured black. RNA is coloured grey. This figure shows the variety of different 





Tetracycline, tobramycin and streptomycin are 
antibiotics that like neomycin, target the bacterial 
ribosome. The tetracycline aptamer boasts a more 
complicated aptamer structure than usually obtained 
by SELEX against a small molecule [83]. The 
tetracycline aptamer consists of three helices, 
creating a binding site out of tertiary contacts 
between the helices. ITC studies of the tetracycline 
riboswitch revealed a two-step binding mechanism 
driven by favourable enthalpy. Tetracycline’s 
interaction with the 30S ribosomal subunit is 
stabilized by hydrogen bonding interactions as 
opposed to the aptamer which has stacking 
interactions with two rings of tetracycline [84].  
 
Tobramycin and Streptomycin 
 
The structures of two aptamers selected for 
tobramycin have been solved [85, 86]. Both aptamer 
tobramycin complexes revealed that the antibiotic 
binds within a deep groove and has multiple 
hydrogen bonding contacts with the RNA. While 
both aptamers share the binding motif, one uses a 
base bulge to widen RNA major groove while the 
other has three mismatch pairs. Since both aptamers 
have comparable binding affinities this example  
 
reveals that changes to the binding site can be diverse.  
The streptomycin aptamer has also been studied by 
the same group that investigated the structure of 
tobramycin and neomycin aptamers [87]. This 





Naturally occurring aptamers consist mainly of 
riboswitches, these sequences affect the secondary 
structure upon binding its ligand to allow for 
transcription of the following sequence. Similarity 
between an artificially selected aptamer and naturally 
occurring RNA can be seen in purine binding RNAs. 
The structure of the purine riboswitch has been 
obtained and reveals that the ligand is encapsulated 
by the RNA [88]. Kinetic studies of this binding 
interaction suggest that the ligand first engages in 
Watson-Crick base pairing with Y74 followed by a 
loop closure that traps the ligand in the binding 
pocket and subsequent formation of hydrogen bonds 
between ligand and RNA. Furthermore mutation 
studies of the purine riboswitch reveal the ability of 
RNA to form a bound-like structure through ligand 
mimicking. The term ligand mimicking is used to 
describe a receptor mimicking the presence of a 
ligand with a residue that has characteristics of the 
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ligand. The mutant purine riboswitch is inactive, with 
one of its nucleotides (G39) occupying the active site 
[89]. While the structure is not yet available other 
biochemical methods suggest that an artificially 
selected adenine aptamer has a similar dependence on 
hydrogen bonding versus stacking interactions [90]. 
The guanine aptamer has a consensus sequence 
similar to tobacco ring spot virus satellite RNA 
hairpin ribozyme [91]. The part of purine riboswitch 
sequence that matches closest to the guanine aptamer 
is involved in binding (Figure 4). The purine 
riboswitch family has been reviewed in more detail 
[92, 93].This family includes the purine riboswitch 
discussed above as well as preQ [93], cyclic-dGMP 
[95] and tetrahydrofolate [96] binding riboswitches.
 
 
Figure 4. RNA aptamers (black) complexed with small molecules (grey). A) Tetracycline aptamer complex, 
PDB ID 3EGZ [84], showing three helix wrapping around target. B) Tobramycin aptamers 
complex, PDB ID 2TOB [85], showing target binding within deep groove. C) Streptomycin 
aptamers complex, PDB ID 1NTB [87], showing S turn wrapping target. D)  Purine aptamer 
complex, PDB ID 2B57 [88], showing target buried within aptamer. E) TPP aptamer complex, 
PDB ID 3K0J [99], showing target interacting with two stems. F) AdoMet aptamer complex PDB 




Thiamine pyrophosphate  
 
Thiamine pyrophosphate (TPP) is a cofactor that 
regulates expression of proteins that are involved in 
the biosynthesis and transport of thiamine [97, 98].  
The regulation occurs via the TPP riboswitch. TPP 
binds to the riboswitch between two parallel stems 
[99]. Investigation into the folding on this riboswitch 
has shown a two-step binding process involving first 
ligand independent secondary structure formation  
 
 
followed by ligand dependent tertiary structure 
formation [100]. 
 
S-Adenosyl methionine  
 
The S-Adenosyl methionine (AdoMet) riboswitch is 
important in the regulation of amino acid 
biosynthesis [101]. The structural study of the 
AdoMet bound aptamer revealed that the interaction 
between RNA and AdoMet primarily involves the 
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adenosine of AdoMet. Investigation of the interaction 
of other metabolites with the AdoMet riboswitch has 
suggested possible regulatory roles [102]. The 
AdoMet riboswitch is a potential target for 




THERMODYNAMICS OF RNA-LIGAND 
INTERACTIONS 
 
The binding of two molecules is generally discussed 
in terms of the free energy change (ΔG), the enthalpy 
change (ΔH), the entropy change (ΔS) and 
dissociation constant (Kd). The thermodynamic 
parameters involved in binding interactions are 
related to each other by the Gibbs Helmholz equation 
(Equation 1).  
    
 ΔG = ΔH – TΔS  (Equation 1) 
 
ΔG is related to the binding affinity by Equation 2, 
with R being the gas constant and T the absolute 
temperature. 
     
 ΔG =RT ln(1/Kd)      (Equation 2) 
 
It is apparent from these equations that binding is 
stronger, Kd lower, the more negative the value of ΔG 
is. From Equation 1 it can be gleaned that a negative 
ΔH will push the value of ΔG to a larger negative 
value. Likewise, a positive value for ΔS will push the 
value of ΔG to a larger negative value. A negative 
value of ΔH will be referred to as favourable ΔH and 
is associated with the increase of interactions 
between ligand and receptor, while a positive value 
of ΔH will be referred to as unfavourable ΔH and is 
associated with reducing number of interactions 
[104]. A negative value of ΔS will be referred to as 
unfavourable ΔS and is associated with a decrease in 
randomness (e.g. restricting movement) while a 
positive value of ΔS will be referred to as favourable 
ΔS and is associated with an increase in randomness 
(e.g. release of water molecules) [104].  
Table 1 shows a summary of thermodynamic data for 
binding of the above mentioned RNA targets. The 
general trend is that binding is driven by favourable 
ΔH which is countered by unfavourable ΔS. The two 
outliers to this trend are the purine riboswitch and the 
DIS HIV kissing loop.
 
 
Table 1: Summary of RNA Binding Thermodynamic Data. 
 
Target RNA ΔH(kcal/mol) ΔS(kcal/mol/K) ΔG(kcal/mol) Kd (nM) References 
Neomycin B Aptamer -21.6 -4.40E-02 -8.49 6.90E+02 [78] 
Tetracycline Aptamer -22.9 -3.52E-02 -12.4 1.00E+00 [95] 
Purine  Riboswitch -40.3 -9.76E-02 -10.7 1.70E+01 [87] 
AdoMet  Riboswitch -24.0 -4.62E-02 -10.2 3.20E+01 [92] 
Tyrosinamide DNA Aptamer -23.7 -5.39E-02 -7.64 2.44E+03 [96] 
Malachite green Aptamer -25.9 -5.69E-02 -8.79 2.80E+02 [97] 
Neomycin B DIS kissing-loop -9.4 2.70E-03 -10.2 3.40E+01 [73] 
Neomycin B Ribosomal A site -16.2 -2.79E-02 -7.90 1.55E+03 [98] 
TPP Riboswitch -58.1 -1.62E-02 -7.70 2.00E+02 [100] 
 
The purine riboswitch has a higher amount of 
favourable enthalpy change while DIS HIV kissing 
loop has a lower ΔH. It is interesting to note that in 
both cases the variation of favourable ΔH is 
compensated by the inverse adjustment in 
unfavourable ΔS. The DIS HIV binding has a 20% 
greater amount of ΔG from charge related 
interactions than the small ribosomal binding site 
[74]. While the purine riboswitch has a significant 
amount of hydrogen bonding [88], this could explain 
the ΔH differences. These two examples suggest that 
artificially selected aptamer binding follows a  
 
 
different trend compared to the naturally occurring 
RNA small molecule interactions. However 
examining the AdoMet riboswitch the 
thermodynamic parameters are almost identical to the 
aptamers. This suggests that there is still too small a 
set of data to make generalizations about the 
thermodynamic trends.  The similarity in energetics 
of binding is eclipsed by the specificity of each 
binding pocket created by differences in sequence  
and geometry of the binding pocket (Table 2).  
An interesting trend is observed in the investigation 
of small molecule binding aptamers, binding involves 
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two stages [84, 105,100]. The first stage is an 
interaction independent of the target and the second 
stage is target dependent. The knowledge of these 
thermodynamic distinguishable steps should provide 






Table 2: RNA Sequences For Various Targets With Structural Features Identified To Showcase The Difference In 




Features PDB Ref# 
Neomycin B GGACUGGGCGAGAAGUUUAGUCC 
three consecutive GU 
base pairs 1NEM [77] 
Tetracycline 
GGGCCUAAAACAUACCAGAGAUCGCCACCCGCGCUUUA
AUCUGGAGAGGUGAAGAAUACGACCACCUAGGCUC three helices 3EGZ [84] 
Tobramycin GGGACUUGGUUUAGGUAAUGAGUCCC 
UG,GU,GA,UU base 
pairs 2TOB [85] 
Streptomycin 
GGAUCGCAUUUGGACUUCUGCC/CGGCACCACGGUCGG





base pairing with Y74 2B57 [88] 
Guanine GGCACGUGUAUUACCCUAGUGGUCGACGUGCC 
structure not 
available n/a [89] 
AdoMet 
GGACGAGGAGCGCUGCAAGCGAGAGCCCGAAGCUCGU




TCGC Two parallel stems 2HOJ [99] 
HIV Rev GGUGUCUUGGAGUGCUGAUCGGACACC 
UAU triple, hydrogen 
bonding with Arg 35 
and Arg 39, 
elongated form 484D [42] 
HIV Rev GGCUGGACUCGUACUUCGGUACUGGAGAAACAGCC 
UAU triple, stacking 
of Trp45, helical form 1ULL [46] 
HIV TAR GGCUGGUCCCAGACGACC kissing complex 2RN1 [50] 
HIV DIS CUUGCUGAAGUGCACACGCAAG kissing complex 3C7R [75] 
HIV Tat GGGAGCUUGAUCCCGGAAACGGUCGAUCGCUCCC 
two adjacent UAU 
triples 1NBK [41] 
MS2 coat 
protein CCGGAGGUCACCACGGG 
A10 makes three 
hydrogen bonds with 
target 1U1Y [56] 
RNA 
polymerase II ACAGCACUGAUUGCGGUCGAGGUAGCUUGAUGG A-form helix 2B63 [60] 
Prion GGAGGAGGAGGA GGGG tetraplane 2RQJ [66] 
Human IgG GGAGGUGCUCCGAAAGGAACUCCA 
G7 stacking with 
Tyr373 3AGV [70] 
NF-κb factor  GAUACUUGAAACUGUAAGGUUGGCGUAUC 
resembles B-form 
DNA 1OOA [61] 
Mammalian 
factor 4A  
GGAGAUCGCACUCCACAUGUGAGUGAGGCCGAAACAUA




A common trend seen with the aptamers selected for 
larger biomolecules is that they mimic the type of 
interactions that already exist in organisms. This is 
seen clearly in the aptamer for TAR HIV RNA, 
which forms a kissing complex similar to that seen in 
HIV DIS [50, 51]. This phenomenon is implied by 
the work with RNA polymerase II aptamer and 
B2RNA competitive binding to RNA polymerase II 
[59].  
In the case of aptamers for antibiotics the naturally 
occurring RNA that binds to the same targets has 
clear differences in binding pockets.  This is a 
reflection of the evolution of RNA, since the 
naturally occurring RNA did not have a selection 
pressure driven purely by affinity to target, but rather 
by their function within the system (cell/virus). As 
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seen in the case of tobramycin with two aptamers that 
use different means to widen binding pocket [85, 86] 
and multiple ATP aptamers [106] it is possible to 
have variations of sequences that have strong binding 
affinity and nature has had multiple variations to 
explore other functions.  
The closer relatives to artificially selected aptamers, 
riboswitches, share similarity, at least in the case of 
adenine. Another example of similarity in sequence 
between artificially selected aptamer and naturally 
occurring RNA is that of the ATP aptamer binding 
motif which was found in a bacterial virus [107]. The 
aptamers selected for small molecules do provide a 
window into the capacity for function inherent to 
RNA, and the roles it could have played in a prebiotic 
world.  
The number of aptamers is increasing as methods to 
select them become more routine and even include in 
silico techniques [108]. 2',4'-Locked RNA aptamers 
are aptamers which include a 2'-O, 4'-C methylene 
link, which confers a C3' endo conformation. This 
change results in an entropic constraint that leads to 
increased affinity for their target [109]. This along 
with other developments in degradation resistant 
nucleotides [110] promises many applications for 
aptamers to come. 
RNA binding usually involves adaptive interactions. 
This has been seen for binding to peptides and small 
molecules [42, 111 – 113]. This behavior makes it 
important to probe the conformational mobility and 
thermodynamics of binding so that the aptamer target 
molecule interaction can be fully characterized. This 
line of investigation can be supplemented by site-
directed modification of the aptamer to change the 
spatial configuration or the energy of the binding 
interaction. For example the binding affinity of tRNA 
gln to glutaminyl-tRNA synthetase was improved by 
studying the related aptamer. The improvements did 
not involve the RNA protein contacts but instead 
were driven by tertiary structure stabilization of the 
RNA [114]. Another important reason for the study 
of structure and thermodynamics of RNA-ligand 
interactions is to understand the nature of RNA-
induced modifications of the ligand itself. A good 
example of such behaviour is seen in the 
conformational changes induced in malachite green 
molecules binding to their cognate aptamer, and these 
changes are significant enough to change the optical 
properties of the dye molecule [115]. This type of 
binding interaction could expand modalities of drug 
interactions, such as aptamer-assisted pro-drug 
delivery.  
Understanding the nature of the interactions between 
target and drug molecule has improved the rational 
design of protein targeting molecules [38]. The 
structure-function paradigm is being applied to 
rational design of biologically active therapeutic 
RNA. This effort is assisted by the use of aptamer 
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